Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
15976 | 613 | 41.8 | 85% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1258 | 8423 | PHAGE DISPLAY//CATALYTIC ANTIBODIES//CATALYTIC ANTIBODY |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | SINGLE DOMAIN ANTIBODY | Author keyword | 76 | 67% | 11% | 69 |
2 | NANOBODY | Author keyword | 76 | 57% | 15% | 91 |
3 | VHH | Author keyword | 67 | 64% | 11% | 65 |
4 | HEAVY CHAIN ANTIBODIES | Author keyword | 41 | 100% | 2% | 15 |
5 | HEAVY CHAIN ANTIBODY | Author keyword | 31 | 76% | 4% | 22 |
6 | SINGLE DOMAIN ANTIBODIES | Author keyword | 24 | 63% | 4% | 24 |
7 | NANOBODIES | Author keyword | 22 | 62% | 4% | 23 |
8 | NEW ANTIGEN RECEPTOR | Author keyword | 14 | 100% | 1% | 7 |
9 | SINGLE DOMAIN ANTIBODY FRAGMENT | Author keyword | 11 | 78% | 1% | 7 |
10 | CELLULAIRE MOL IMMUNOL | Address | 10 | 73% | 1% | 8 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SINGLE DOMAIN ANTIBODY | 76 | 67% | 11% | 69 | Search SINGLE+DOMAIN+ANTIBODY | Search SINGLE+DOMAIN+ANTIBODY |
2 | NANOBODY | 76 | 57% | 15% | 91 | Search NANOBODY | Search NANOBODY |
3 | VHH | 67 | 64% | 11% | 65 | Search VHH | Search VHH |
4 | HEAVY CHAIN ANTIBODIES | 41 | 100% | 2% | 15 | Search HEAVY+CHAIN+ANTIBODIES | Search HEAVY+CHAIN+ANTIBODIES |
5 | HEAVY CHAIN ANTIBODY | 31 | 76% | 4% | 22 | Search HEAVY+CHAIN+ANTIBODY | Search HEAVY+CHAIN+ANTIBODY |
6 | SINGLE DOMAIN ANTIBODIES | 24 | 63% | 4% | 24 | Search SINGLE+DOMAIN+ANTIBODIES | Search SINGLE+DOMAIN+ANTIBODIES |
7 | NANOBODIES | 22 | 62% | 4% | 23 | Search NANOBODIES | Search NANOBODIES |
8 | NEW ANTIGEN RECEPTOR | 14 | 100% | 1% | 7 | Search NEW+ANTIGEN+RECEPTOR | Search NEW+ANTIGEN+RECEPTOR |
9 | SINGLE DOMAIN ANTIBODY FRAGMENT | 11 | 78% | 1% | 7 | Search SINGLE+DOMAIN+ANTIBODY+FRAGMENT | Search SINGLE+DOMAIN+ANTIBODY+FRAGMENT |
10 | IGNAR | 9 | 64% | 1% | 9 | Search IGNAR | Search IGNAR |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HEAVY CHAIN ANTIBODIES | 180 | 71% | 23% | 144 |
2 | SINGLE DOMAIN ANTIBODY | 53 | 63% | 9% | 53 |
3 | VHH | 38 | 93% | 2% | 14 |
4 | SINGLE DOMAIN ANTIBODIES | 35 | 46% | 9% | 58 |
5 | VH DOMAINS | 24 | 82% | 2% | 14 |
6 | SMALL RECOGNITION UNITS | 22 | 68% | 3% | 19 |
7 | DOMAIN ANTIBODY FRAGMENTS | 21 | 51% | 5% | 30 |
8 | PINHOLE SPECT MICRO CT | 21 | 73% | 3% | 16 |
9 | NANOBODIES | 18 | 51% | 4% | 25 |
10 | LOOP STRUCTURES | 17 | 68% | 2% | 15 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Nanobodies: Natural Single-Domain Antibodies | 2013 | 111 | 147 | 71% |
Nanobody-based products as research and diagnostic tools | 2014 | 24 | 82 | 71% |
Properties, production, and applications of camelid single-domain antibody fragments | 2007 | 201 | 85 | 73% |
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity | 2009 | 123 | 119 | 56% |
The development of nanobodies for therapeutic applications | 2009 | 61 | 129 | 74% |
Biotechnological applications of recombinant single-domain antibody fragments | 2011 | 34 | 183 | 58% |
Nanobodies as novel agents for disease diagnosis and therapy | 2013 | 11 | 81 | 70% |
Immuno-imaging using nanobodies | 2011 | 26 | 27 | 59% |
Stability engineering of the human antibody repertoire | 2014 | 11 | 84 | 29% |
Single-domain antibodies as building blocks for novel therapeutics | 2008 | 69 | 76 | 67% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CELLULAIRE MOL IMMUNOL | 10 | 73% | 1.3% | 8 |
2 | CELLULAR MOL INTERACT | 3 | 29% | 1.6% | 10 |
3 | VIVO CELLULAR MOL IMAGING | 3 | 29% | 1.6% | 10 |
4 | MOL CELLULAR INTERACT | 3 | 10% | 5.1% | 31 |
5 | VENOM BIOTHER EUT MOL | 3 | 60% | 0.5% | 3 |
6 | ALGEMENE BIOL | 2 | 67% | 0.3% | 2 |
7 | CELLULAR MOL IMMUNOL CMIM | 2 | 67% | 0.3% | 2 |
8 | MOL BIOTECHNOL 7 | 2 | 67% | 0.3% | 2 |
9 | CELLULAR ARCHITECTURE DYNAM | 2 | 30% | 1.0% | 6 |
10 | GDR2352 | 2 | 50% | 0.5% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000208462 | SCFV//SINGLE CHAIN FV//PHAGE DISPLAY |
2 | 0.0000155457 | AFFIBODY MOLECULE//AFFIBODY MOLECULES//AFFIBODY |
3 | 0.0000113464 | CANONICAL STRUCTURES//CDR CONFORMATION//ANTIBODY STRUCTURE |
4 | 0.0000077012 | AFFINITY MASS SPECTROMETRY//PEPTIDE CHIP ANALYSIS//PROTEOLYTIC EPITOPE EXCISION |
5 | 0.0000067570 | SORBIN//NONCOMPETITIVE IMMUNOASSAY//PHAGE ANTI IMMUNOCOMPLEX ASSAY |
6 | 0.0000053341 | FCRN//NEONATAL FC RECEPTOR//TARGET MEDIATED DRUG DISPOSITION |
7 | 0.0000049426 | HOMOPHILIC ANTIBODY//ADV DIAGNOST THER EUT//ANTIBODY FAB FRAGMENT |
8 | 0.0000045732 | LLAMA//ALPACA//LLAMAS |
9 | 0.0000044801 | OCULOPHARYNGEAL MUSCULAR DYSTROPHY//PABPN1//OPMD |
10 | 0.0000042513 | GINBUNA CRUCIAN CARP//NONSPECIFIC CYTOTOXIC CELLS//ANTIBODY PHYLOGENY |